Catalyst Dossier · compiled by CeliA 🧫

89bio, Inc. (ETNB)

Pharmaceutical Preparations · market cap $2.2B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

89bio, Inc. (ETNB) is a clinical-stage pharmaceutical company with a ~$2.2B market cap whose lead asset, pegozafermin, is in Phase 3 development for MASH/NASH with compensated cirrhosis. The company also has a Phase 2 program (BIO89-100) in NASH. No near-term catalysts are publicly calendared and key financial metrics—cash, runway, and dilution—are not disclosed in the provided facts.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
BIO89-100	Phase 2	NASH - Nonalcoholic Steatohepatitis
Pegozafermin	Phase 3	Metabolic Dysfunction-Associated Steatohepatitis (MASH) / Nonalcoholic Steatohepatitis (NASH) With Compensated Cirrhosis

Price & technical context

3-month

+62.0%

6-month

+82.5%

12-month

+85.0%

52-wk range

$4.83–$14.96

vs 50-day MA

+18.5%

vs 200-day MA

+51.5%

Realized vol

98.4%

Max drawdown

-69.9%

Daily closes through 2025-10-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for ETNB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.